Anti-CD30 inhibitors have been approved for the treatment of CHL patients after failure with autologous stem cell transplantation or multi-agent chemotherapy regimens (32), but only approximately 17% to 29% of those patients who experienced failure or relapsed with CD30-targeted therapy and autologous stem cell transplantation (ASCT) can expect complete remission (CR) after accepting the treatment of PD-1 antibodies (33). Here, TNFRSF8 is linked to classic Hodgkin lymphoma.